SCHEMBL5459745

SCHEMBL5459745

COc1ccc(S(=O)(=O)N(c2ccc(Cl)cc2Cc2c(F)cccc2F)C(F)C(=O)O)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.46
HCRTR2 O43614 2/20 0.43
HCRTR1 O43613 1/20 0.43
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MCOLN3 Q8TDD5 3/20 0.40
POLB P06746 2/20 0.40
HTT P42858 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253172 0.92 HTT (0.48) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL3253166 0.92 HTT (0.48) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL8272210 0.89 PKM (0.45) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL4871558 0.88 PKM (0.46) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL3249066 0.88 PKM (0.46) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL3250138 0.88 PSEN1 (0.50) PKMHCRTR2HCRTR1
SCHEMBL3249207 0.87 PKM (0.46) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL3256226 0.87 PKM (0.44) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL3251909 0.85 HCRTR2 (0.44) PKMHCRTR2HCRTR1MAPTSMN1; SMN2
SCHEMBL3247826 0.85 PKM (0.41) PKMHCRTR2HCRTR1MAPTMCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 PKM 2524/4885HCRTR2 1/4885HCRTR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.